细胞疗法製造市场－全球产业规模、份额、趋势、竞争格局、机会及预测（依治疗方法、细胞来源、营运规模、供应来源、应用、最终用户、地区和竞争格局划分），2021-2031年

全球细胞治疗製造市场预计将从2025年的57.1亿美元成长到2031年的114.2亿美元，复合年增长率（CAGR）为12.25%。该行业涵盖了分离、基因改造、扩增和冷冻保存用于自体或异体移植疗法的活性细胞所需的专业生物製程活动。市场成长的主要驱动力是全球肿瘤和罕见遗传疾病发生率的不断上升，加剧了对治疗性介入的迫切需求。同时，法规环境的日趋成熟也促进了核准的加速以及对专用生产基础设施的投资。

根据美国基因与细胞治疗学会 (ASGCT) 和 Citeline 的数据，预计到 2025 年，全球基因和细胞治疗药物开发平臺将保持强劲势头，届时将有超过 3200 项临床试验正在进行中。虽然如此庞大的临床候选药物数量推动了对大规模生产能力的需求，但该产业在成本效益方面也面临严峻挑战。具体而言，如何维持从病人到病人的供应链完整性，以及扩大生产规模的难度，都对降低这些先进医疗疗法的高昂销货成本构成了重大障碍。

市场驱动因素

支持性的法规环境和加快核准流程正在从根本上改变製造业，加速复杂治疗方法的商业化进程。随着监管机构优化审查流程，该行业正迅速从临床规模的生产转向大规模商业化生产，市场参与企业数量的增加便是这一转变的有力佐证。根据再生医学联盟（Alliance for Regenerative Medicine）统计，截至2025年1月，该产业在2024年已获得9种新产品核可。如此激增的核准需要一条具有韧性的供应链和可扩展的基础设施，能够在加快审批速度的同时满足严格的品质标准。

因此，为了避免自建设施带来的巨额资本成本和技术负担，製药公司越来越依赖合约研发生产力机构（CDMO）。为了满足这种外包需求，CDMO正在积极扩张。例如，三星生物製剂于2025年12月宣布计画投资48亿美元建造一座新的生物园区，该园区将配备新一代细胞和基因治疗技术。牛津生物医药公司也反映了这一趋势，该公司报告称，截至2025年9月，其上半年已获得价值1.49亿英镑的新客户订单，凸显了专业合作伙伴的重要性。

市场挑战

全球细胞疗法生产市场成长的主要障碍是成本效益严重不足以及维持供应链完整性的困难。由于劳力密集且扩充性的工作流程，导致销货成本，使得治疗费用高到医疗报销体系无法承受的地步。这种经济压力限制了可接受治疗的患者群体，并阻碍了针对更广泛疾病的治疗方法的商业化。因此，该市场实际上仅限于支付方能够承担高成本的特定适应症。

根据再生医学联盟预测，到2025年，全球再生医学领域75%的收入将来自不到10种上市产品。这种收入集中度凸显了强大的临床研发管线与实际商业性可行性之间的脱节，并显示将临床成功转化为盈利且可扩展的生产营运存在重大瓶颈。因此，扩大生产规模所带来的财务风险对许多开发商而言仍然难以承受，由于无法支持多样化的治疗方法，市场扩张受到阻碍。

市场趋势

采用自动化和封闭式系统处理平台正成为解决产业劳动密集瓶颈和一致性问题的关键方案。製造商正积极利用整合式智慧工厂模组，以精准的机器人操作取代人工，确保批次均一性并降低污染风险。这种技术革新使得产能无需成比例增加设施规模或人员即可显着提升，例如，Cellares公司于2024年9月在新泽西州运作的工厂，每年可生产多达4万剂标准CAR-T细胞疗法。

同时，分散式和照护现场生产模式的兴起正在革新传统的集中式供应链，将生产能力置于临床环境之内或附近。这种策略透过在现场处理患者样本，显着缩短了从静脉到静脉的运输时间，并减少了物流障碍，有效地将医院转变为生物製造中心。德克萨斯大学MD安德森癌症中心于2024年11月推出了一个新的研究机构，旨在加速细胞治疗方法的内部发现和生产，该机构获得了超过8000万美元的资助，这正是领先的学术和临床机构如何资助这一变革的一个例证。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球细胞疗法製造市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗方法（T细胞疗法、树突细胞疗法、癌细胞疗法、干细胞疗法）
  • 依细胞来源（自体细胞与异体细胞）
  • 依企业规模（临床前、临床、商业）
  • 依供应来源（内部生产与契约製造）划分
  • 依应用领域（肿瘤科、心血管疾病科、整形外科疾病科等）
  • 依最终用户（製药/生技公司、学术/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美细胞疗法製造市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲细胞疗法製造市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太细胞疗法製造市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲细胞疗法製造市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲细胞疗法製造市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球细胞疗法製造市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Lonza
• Thermo Fisher
• Catalent
• WuXi AppTec
• Novartis
• Gilead
• Bristol Myers Squibb
• Merck KGaA
• Cytiva
• Charles River

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cell Therapy Manufacturing Market is projected to expand from USD 5.71 Billion in 2025 to USD 11.42 Billion by 2031, reflecting a compound annual growth rate of 12.25%. This sector comprises specialized bioprocessing activities essential for isolating, genetically modifying, expanding, and cryopreserving viable cells used in autologous or allogeneic therapies. Market growth is primarily propelled by the increasing global prevalence of oncological and rare genetic disorders, creating an urgent need for curative interventions, while maturing regulatory environments encourage expedited approvals and investment in dedicated production infrastructure.

Data from the American Society of Gene & Cell Therapy and Citeline indicates that the global pipeline remained strong in 2025, with over 3,200 active trials. While this high volume of clinical candidates drives the need for extensive manufacturing capacity, the industry faces substantial hurdles related to cost-efficiency. Specifically, the complexity involved in preserving supply chain integrity from patient to patient, combined with the difficulties of scaling production, creates a significant barrier to lowering the high cost of goods sold for these advanced medical treatments.

Market Driver

Supportive regulatory environments and accelerated approval pathways are fundamentally transforming the manufacturing sector by speeding up the commercial launch of complex therapies. As health authorities optimize review procedures, the industry is rapidly moving from clinical-scale operations to high-volume commercial production, a shift underscored by a growing number of market participants. According to the Alliance for Regenerative Medicine, the sector achieved nine new product approvals in 2024 as of January 2025; this surge in authorizations demands resilient supply chains and scalable infrastructure capable of meeting strict quality standards under expedited timelines.

Consequently, there is an increasing dependence on Contract Development and Manufacturing Organizations as developers aim to avoid the heavy capital costs and technical burdens of building internal facilities. CDMOs are aggressively expanding to meet this outsourcing demand, as seen in Samsung Biologics' December 2025 announcement of a $4.8 billion investment for a new bio-campus featuring next-generation cell and gene therapy capabilities. This trend is further evidenced by Oxford Biomedica, which reported signing £149 million in new client orders during the first half of the year in September 2025, underscoring the critical role of specialized partners.

Market Challenge

The primary obstacles restricting the Global Cell Therapy Manufacturing Market's growth are the significant lack of cost-efficiency and the difficulties associated with maintaining supply chain integrity. High costs of goods sold, resulting from labor-intensive and unscalable workflows, inflate therapy prices to levels that challenge healthcare reimbursement systems. This economic pressure restricts the accessible patient demographic and deters the commercialization of treatments for broader conditions, effectively confining the market to niche indications where high costs are absorbed by payers.

According to the Alliance for Regenerative Medicine, 75% of the sector's global revenue in 2025 came from fewer than ten commercial products. This intense revenue concentration reveals a disconnect between a strong clinical pipeline and actual commercial viability, indicating a major bottleneck in converting clinical successes into profitable, scalable manufacturing operations. As a result, market expansion is hindered by the inability to support a diverse array of therapies, as the financial risks involved in scaling production remain prohibitively high for many developers.

Market Trends

The implementation of automated and closed-system processing platforms is becoming a vital solution to the industry's labor-intensive bottlenecks and consistency issues. Manufacturers are increasingly utilizing integrated smart factory modules that substitute manual handling with robotic precision, ensuring batch uniformity and reducing contamination risks. This technological evolution enables massive throughput scaling without requiring proportional increases in facility size or staff, as demonstrated by Cellares in September 2024, when it commissioned a New Jersey facility capable of producing up to 40,000 standard CAR-T cell therapy doses annually.

Simultaneously, the rise of decentralized and point-of-care production models is disrupting traditional centralized supply chains by placing manufacturing capabilities within or near clinical environments. This strategy drastically cuts vein-to-vein timelines and logistical hurdles by processing patient material on-site, effectively turning hospitals into biomanufacturing centers. Major academic and clinical institutions are funding this shift, as illustrated by The University of Texas MD Anderson Cancer Center's November 2024 launch of a new institute, backed by over $80 million, to accelerate the internal discovery and manufacturing of cell therapies.

Key Market Players

• Lonza
• Thermo Fisher
• Catalent
• WuXi AppTec
• Novartis
• Gilead
• Bristol Myers Squibb
• Merck KGaA
• Cytiva
• Charles River

Report Scope

In this report, the Global Cell Therapy Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Therapy Manufacturing Market, By Therapy

• T-Cell Therapies
• Dendritic Cell Therapies
• Tumor Cell Therapies
• Stem Cell Therapies

Cell Therapy Manufacturing Market, By Source of Cell

• Autologous v/s Allogenic

Cell Therapy Manufacturing Market, By Scale of Operation

• Preclinical
• Clinical
• Commercial

Cell Therapy Manufacturing Market, By Source

• In-House v/s Contract Manufacturing

Cell Therapy Manufacturing Market, By Application

• Oncology
• Cardiovascular Diseases
• Orthopedic Diseases
• Others

Cell Therapy Manufacturing Market, By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

Cell Therapy Manufacturing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Therapy Manufacturing Market.

Available Customizations:

Global Cell Therapy Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Therapy Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
  • 5.2.2. By Source of Cell (Autologous v/s Allogenic)
  • 5.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
  • 5.2.4. By Source (In-House v/s Contract Manufacturing)
  • 5.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
  • 5.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
  • 5.2.7. By Region
  • 5.2.8. By Company (2025)
• 5.3. Market Map

6. North America Cell Therapy Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Source of Cell
  • 6.2.3. By Scale of Operation
  • 6.2.4. By Source
  • 6.2.5. By Application
  • 6.2.6. By End User
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell Therapy Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Source of Cell
      • 6.3.1.2.3. By Scale of Operation
      • 6.3.1.2.4. By Source
      • 6.3.1.2.5. By Application
      • 6.3.1.2.6. By End User
  • 6.3.2. Canada Cell Therapy Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Source of Cell
      • 6.3.2.2.3. By Scale of Operation
      • 6.3.2.2.4. By Source
      • 6.3.2.2.5. By Application
      • 6.3.2.2.6. By End User
  • 6.3.3. Mexico Cell Therapy Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Source of Cell
      • 6.3.3.2.3. By Scale of Operation
      • 6.3.3.2.4. By Source
      • 6.3.3.2.5. By Application
      • 6.3.3.2.6. By End User

7. Europe Cell Therapy Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Source of Cell
  • 7.2.3. By Scale of Operation
  • 7.2.4. By Source
  • 7.2.5. By Application
  • 7.2.6. By End User
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell Therapy Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Source of Cell
      • 7.3.1.2.3. By Scale of Operation
      • 7.3.1.2.4. By Source
      • 7.3.1.2.5. By Application
      • 7.3.1.2.6. By End User
  • 7.3.2. France Cell Therapy Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Source of Cell
      • 7.3.2.2.3. By Scale of Operation
      • 7.3.2.2.4. By Source
      • 7.3.2.2.5. By Application
      • 7.3.2.2.6. By End User
  • 7.3.3. United Kingdom Cell Therapy Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Source of Cell
      • 7.3.3.2.3. By Scale of Operation
      • 7.3.3.2.4. By Source
      • 7.3.3.2.5. By Application
      • 7.3.3.2.6. By End User
  • 7.3.4. Italy Cell Therapy Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Source of Cell
      • 7.3.4.2.3. By Scale of Operation
      • 7.3.4.2.4. By Source
      • 7.3.4.2.5. By Application
      • 7.3.4.2.6. By End User
  • 7.3.5. Spain Cell Therapy Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Source of Cell
      • 7.3.5.2.3. By Scale of Operation
      • 7.3.5.2.4. By Source
      • 7.3.5.2.5. By Application
      • 7.3.5.2.6. By End User

8. Asia Pacific Cell Therapy Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Source of Cell
  • 8.2.3. By Scale of Operation
  • 8.2.4. By Source
  • 8.2.5. By Application
  • 8.2.6. By End User
  • 8.2.7. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell Therapy Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Source of Cell
      • 8.3.1.2.3. By Scale of Operation
      • 8.3.1.2.4. By Source
      • 8.3.1.2.5. By Application
      • 8.3.1.2.6. By End User
  • 8.3.2. India Cell Therapy Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Source of Cell
      • 8.3.2.2.3. By Scale of Operation
      • 8.3.2.2.4. By Source
      • 8.3.2.2.5. By Application
      • 8.3.2.2.6. By End User
  • 8.3.3. Japan Cell Therapy Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Source of Cell
      • 8.3.3.2.3. By Scale of Operation
      • 8.3.3.2.4. By Source
      • 8.3.3.2.5. By Application
      • 8.3.3.2.6. By End User
  • 8.3.4. South Korea Cell Therapy Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Source of Cell
      • 8.3.4.2.3. By Scale of Operation
      • 8.3.4.2.4. By Source
      • 8.3.4.2.5. By Application
      • 8.3.4.2.6. By End User
  • 8.3.5. Australia Cell Therapy Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Source of Cell
      • 8.3.5.2.3. By Scale of Operation
      • 8.3.5.2.4. By Source
      • 8.3.5.2.5. By Application
      • 8.3.5.2.6. By End User

9. Middle East & Africa Cell Therapy Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Source of Cell
  • 9.2.3. By Scale of Operation
  • 9.2.4. By Source
  • 9.2.5. By Application
  • 9.2.6. By End User
  • 9.2.7. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell Therapy Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Source of Cell
      • 9.3.1.2.3. By Scale of Operation
      • 9.3.1.2.4. By Source
      • 9.3.1.2.5. By Application
      • 9.3.1.2.6. By End User
  • 9.3.2. UAE Cell Therapy Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Source of Cell
      • 9.3.2.2.3. By Scale of Operation
      • 9.3.2.2.4. By Source
      • 9.3.2.2.5. By Application
      • 9.3.2.2.6. By End User
  • 9.3.3. South Africa Cell Therapy Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Source of Cell
      • 9.3.3.2.3. By Scale of Operation
      • 9.3.3.2.4. By Source
      • 9.3.3.2.5. By Application
      • 9.3.3.2.6. By End User

10. South America Cell Therapy Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Source of Cell
  • 10.2.3. By Scale of Operation
  • 10.2.4. By Source
  • 10.2.5. By Application
  • 10.2.6. By End User
  • 10.2.7. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Therapy Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Source of Cell
      • 10.3.1.2.3. By Scale of Operation
      • 10.3.1.2.4. By Source
      • 10.3.1.2.5. By Application
      • 10.3.1.2.6. By End User
  • 10.3.2. Colombia Cell Therapy Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Source of Cell
      • 10.3.2.2.3. By Scale of Operation
      • 10.3.2.2.4. By Source
      • 10.3.2.2.5. By Application
      • 10.3.2.2.6. By End User
  • 10.3.3. Argentina Cell Therapy Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Source of Cell
      • 10.3.3.2.3. By Scale of Operation
      • 10.3.3.2.4. By Source
      • 10.3.3.2.5. By Application
      • 10.3.3.2.6. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell Therapy Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Lonza
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher
• 15.3. Catalent
• 15.4. WuXi AppTec
• 15.5. Novartis
• 15.6. Gilead
• 15.7. Bristol Myers Squibb
• 15.8. Merck KGaA
• 15.9. Cytiva
• 15.10. Charles River

16. Strategic Recommendations

17. About Us & Disclaimer